Federated Hermes’s Xenon Pharmaceuticals XENE Stock Holding History

Federated Hermes’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.5M	Buy	972,237 +300,000	+45%	+$13.8M	0.09%	235
2025 Q4	$30.1M	Buy	672,237 +439,737	+189%	+$18.5M	0.05%	360
2025 Q3	$9.33M	Hold	232,500	–	–	0.02%	583
2025 Q2	$7.28M	Hold	232,500	–	–	0.01%	639
2025 Q1	$7.8M	Sell	232,500 -326,000	-58%	-$12.4M	0.02%	611
2024 Q4	$21.9M	Sell	558,500 -177,700	-24%	-$7.35M	0.05%	393
2024 Q3	$29M	Buy	736,200 +1,645	+0.2%	+$66.3K	0.06%	345
2024 Q2	$28.6M	Sell	734,555 -345	-0%	-$13.8K	0.07%	319
2024 Q1	$31.6M	Buy	734,900 +388,304	+112%	+$17.9M	0.07%	316
2023 Q4	$16M	Buy	+346,596	New	+$12.2M	0.04%	443

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Federated Hermes's XENE Position: Q1 2026 in Review

Federated Hermes increased its Xenon Pharmaceuticals (XENE) stake by 45% in Q1 2026, buying an estimated $13.8M and bringing the position to 972,237 shares worth $56.5M. The position accounts for 0.09% of the portfolio, ranked #235.

Federated Hermes first reported a position in XENE in Q4 2023 and has held it in 10 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Federated Hermes held 972,237 shares of Xenon Pharmaceuticals worth $56.5M as of Q1 2026.
Federated Hermes bought 300,000 Xenon Pharmaceuticals shares in Q1 2026, an estimated $13.8M.
Xenon Pharmaceuticals made up 0.09% of Federated Hermes's portfolio in Q1 2026, its #235 holding.
Federated Hermes first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.